Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease

D Moatti1, S Faure, F Fumeron

  • 1INSERM U479, Faculté Bichat, Paris, France.

Blood
|March 27, 2001
PubMed

Insights

The CX3CR1 I249 genetic variant in monocytes may protect against coronary artery disease. This finding suggests CX3CR1

Area of Science:

  • Cardiovascular Genetics
  • Immunology
  • Molecular Biology

Background:

  • Coronary atherosclerosis is a leading cause of death globally.
  • Monocytes are key players in atherosclerosis, migrating into vessel walls.
  • Chemokine receptors like CX3CR1 (chemokine (C-X3-C) receptor 1) mediate monocyte migration and adhesion.

Purpose of the Study:

  • To investigate the role of CX3CR1 genetic variants in coronary artery disease.
  • To determine if CX3CR1 genotypes are associated with acute coronary syndromes.

Main Methods:

  • Genotyping of CX3CR1 alleles (I249 and M280) in patients with acute coronary syndromes and healthy controls.
  • Analysis of CX3CR1 genotype associations with acute coronary events.
  • Functional analysis of peripheral blood mononuclear cells to assess fractalkine binding.

Main Results:

  • CX3CR1 I249 heterozygosity was associated with a significantly reduced risk of acute coronary events (OR=0.43).
  • This association was independent of traditional coronary risk factors.
  • Individuals with CX3CR1 I249 heterozygosity showed decreased fractalkine binding sites on their cells.

Conclusions:

  • CX3CR1 I249 acts as an independent genetic risk factor for coronary artery disease.
  • CX3CR1 signaling is implicated in the pathogenesis of atherosclerosis.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...